

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

Dent, Paul et al.

Examiner: Sznajdman, Marcos L

INTERNATIONAL APPLICATION NO: PCT/IB03/01418

FILED: April 04, 2003

U.S. APPLICATION NO: 10/510531

35 USC §371 DATE: March 30, 2005

FOR: Combination of Glivec (STI571) with a Cyclin-dependent Kinase
Inhibitor, Especially Flavopiridol, in the Treatment of Cancer

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

NOTICE OF APPEAL


Sir:

Applicants hereby appeal to the Board of Patent Appeals and Interferences from the
Office Action dated January 6, 2010 finally rejecting claims 17-22.

- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of
\$540 for payment of the appeal fee. An additional copy of this paper is here enclosed.
The Commissioner is hereby authorized to charge any additional fees which may be
required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.
- ☐ The appeal fee was paid in a previous appeal herein. The examiner re-opened
prosecution prior to any decision by the Board of Patent Appeals and Interferences. No
fee is now due.
- ☐ Enclosed is a Petition for Extension of Time.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-7824

Respectfully submitted,


George Dohmann
Attorney for Applicant
Reg. No. 33,593

Date: April 6, 2010